Gene silencing associated with aberrant methylation of promoter region CpG islands is one mechanism in which tumor suppressor genes are inactivated in human cancers. Recently, we identified a novel gene, Target of Methylation-associated Silencing-1 (TMS1) (also called ASC), which is aberrantly methylated and silenced in human breast cancers. To further investigate the mechanism of TMS1 silencing, we defined the transcription initiation site and detailed the DNA methylation pattern of the TMS1 CpG island in normal breast epithelial cells, breast cancer cell lines, and primary tumors. We find that in normal cells, the TMS1 CpG island lies within a 1.2 kb unmethylated domain, the 5 0 boundary of which is in close proximity to the transcription initiation site. In breast cancer cell lines, this boundary appeared to be unstable in that methylation tended to accumulate in the 5 0 end of the CpG island relative to normal epithelial cells. In contrast, the 3 0 methylation boundary remained intact. Gene silencing was not correlated with the methylation of specific CpG sites nor the inability to transactivate the TMS1 promoter, but was correlated with the percentage of alleles in the population exhibiting dense methylation across the entire CpG island. Using 5-aza-deoxycytidine to reactivate TMS1 in methylated and silent cell lines, and a cassette methylation strategy to determine the impact of methylation on different parts of the promoter, we find that demethylation of a small region immediately surrounding the transcription start site is critical to TMS1 expression. Our data support the idea that gene silencing and dense methylation are tightly coupled events that affect individual chromosomal copies of TMS1 in an all-or-none manner. The transition to this stably repressed state may be facilitated by spreading of methylation into the proximal promoter and direct effects of methylation on TMS1 transcription.
Gene silencing associated with aberrant methylation of promoter region CpG islands is one mechanism in which tumor suppressor genes are inactivated in human cancers. Recently, we identified a novel gene, Target of Methylation-associated Silencing-1 (TMS1) (also called ASC), which is aberrantly methylated and silenced in human breast cancers. To further investigate the mechanism of TMS1 silencing, we defined the transcription initiation site and detailed the DNA methylation pattern of the TMS1 CpG island in normal breast epithelial cells, breast cancer cell lines, and primary tumors. We find that in normal cells, the TMS1 CpG island lies within a 1.2 kb unmethylated domain, the 5 0 boundary of which is in close proximity to the transcription initiation site. In breast cancer cell lines, this boundary appeared to be unstable in that methylation tended to accumulate in the 5 0 end of the CpG island relative to normal epithelial cells. In contrast, the 3 0 methylation boundary remained intact. Gene silencing was not correlated with the methylation of specific CpG sites nor the inability to transactivate the TMS1 promoter, but was correlated with the percentage of alleles in the population exhibiting dense methylation across the entire CpG island. Using 5-aza-deoxycytidine to reactivate TMS1 in methylated and silent cell lines, and a cassette methylation strategy to determine the impact of methylation on different parts of the promoter, we find that demethylation of a small region immediately surrounding the transcription start site is critical to TMS1 expression. Our data support the idea that gene silencing and dense methylation are tightly coupled events that affect individual chromosomal copies of TMS1 in an all-or-none manner. The transition to this stably repressed state may be facilitated by spreading of methylation intoIntroduction Breast cancer kills over 40 000 women in the US each year and is the leading cause of cancer death in women worldwide. Inherited dominant susceptibility alleles such as mutations in BRCA1, BRCA2, and PTEN account for less than 10% of breast cancer cases (Martin and Weber, 2000) . The remaining cases are sporadic in nature and arise as a result of acquired alterations in oncogenes and tumor suppressor genes, the most common of which include amplifications of the erbB2/ HER2, c-myc, and cyclin D2 oncogenes and mutations in p53 (Ingvarsson, 1999) . Gene silencing associated with the aberrant methylation of promoter region CpG islands is an acquired epigenetic mechanism that serves as an alternative to genetic alterations in the inactivation of tumor suppressors and other genes in human cancers (Baylin et al., 1998; Jones and Laird, 1999) . In human breast cancer, methylation-associated silencing has been implicated in the loss of function of several genes with established roles in tumor suppression and disease progression including estrogen receptor, CDKN2A, E-cadherin, and BRCA1 . The recent identification of new genes that are frequently methylated in human breast cancer, for example, 14-3-3 sigma (Ferguson et al., 1997) , RASSF1A (Dammann et al., 2001) , and HIN-1 (Krop et al., 2001) ) have pointed to the potential involvement of novel pathways in the pathogenesis of breast cancer.
CpG islands are regions of DNA with an unusually high frequency of the dinucleotide CpG relative to the remainder of the genome (Bird, 1986) . More than half the genes in the human genome are associated with CpG islands, which often overlap the promoter region and first exon of the gene, although the exact position of the CpG island with regard to the transcriptional unit varies from gene to gene (Bird, 1986) . Whereas most of the CpG sites in the human genome are methylated, those in CpG islands remain unmethylated in normal tissues. Notable exceptions include CpG islands on the inactive X chromosome and those associated with imprinted genes where methylation plays a role in the establishment of allele-specific gene repression (Mann et al., 2000) .
Whether it occurs as part of a normal developmental program, or aberrantly in human cancers, CpG island methylation is associated with stable gene repression. In ONCOGENOMICS the methylated state, CpG islands take on a transcriptionally unfavorable, 'closed' chromatin conformation characterized by nuclease resistance and hypoacetylated core histones (Bird and Wolffe, 1999) . The mechanistic link between DNA methylation and alterations in chromatin structure is believed to be mediated by recruitment of methyl CpG binding proteins (MBDs) and associated corepressor complexes, such as the Mi-2/ NuRD and MeCP1 complexes, which, in addition to MBDs, contain histone deacetylase and nucleosome remodeling activities (Wade et al., 1999; Zhang et al., 1999; Wade, 2001; Feng et al., 2002) . In addition to indirect effects on local chromatin architecture, DNA methylation can also act locally to directly prevent the binding of some transcription factors to their recognition sequence (Eden and Cedar, 1994; Campanero et al., 2000) . These two mechanisms need not be mutually exclusive as methylation of particular CpGs may block the binding of a transcription factor, while creating a binding site for an MBD (Di Fiore et al., 1999) . At present, the exact mechanism by which CpG islands are protected from methylation in normal cells, acquire methylation in cancer cells, and progress to this transcriptionally inert state are not well understood.
Recently, we identified a novel gene, Target of Methylation-associated Silencing-1 (TMS1), that is aberrantly methylated and silenced in a significant proportion of human breast cancers. TMS1 (also known as ASC and PYCARD) was originally identified in a screen for downstream targets of methylation-mediated silencing induced by ectopic expression of human DNA methyltransferase-1 (DNMT1) (Conway et al., 2000) . Subsequent studies indicated that loss of TMS1 expression in breast cancer cell lines correlated with methylation of selected sites in the TMS1 CpG island (Conway et al., 2000) . In all, 40% of primary breast tumors exhibited aberrant methylation of TMS1 (Conway et al., 2000) . TMS1 was also identified in an 'in silico' screen for mRNAs that were under-represented in breast cancer cDNA libraries (Schmitt et al., 1999) . In a recent large-scale gene expression profiling study, TMS1 was found to be downregulated by at least twofold in 27 of 117 primary breast tumors (van 't Veer et al., 2002) . In gene replacement studies, we showed that TMS1 suppressed the growth of breast cancer cells (Conway et al., 2000) . Taken together, these data implicate TMS1 as a potential tumor suppressor for breast cancer.
To further define the role of methylation in TMS1 gene silencing, we defined the transcription start site used by breast cells and detailed the patterns of DNA methylation of 107 CpG sites across the TMS1 locus in normal human mammary epithelial cells, breast cancer cell lines, and primary breast tumors. We find that the TMS1 CpG island lies within a 1.2 kb unmethylated domain, the 5 0 boundary of which is in close proximity to the transcription start site. TMS1 silencing was not correlated with methylation of specific CpG sites, but rather was associated with the dense methylation across the CpG island. Using 5-azadeoxycitidine [5-Aza-CdR] to reactivate TMS1 in TMS1 negative breast cancer cells and a cassette methylation strategy to selectively methylate different parts of the TMS1 promoter, we find that demethylation of CpGs in a small region immediately surrounding transcription start is critical to TMS1 transcription. Taken together, our data suggest that direct effects of methylation on the TMS1 promoter may contribute to the establishment of the more stable gene repression associated with dense methylation and altered chromatin architecture.
Results
To examine the role of DNA methylation in TMS1 silencing, we first characterized the TMS1 locus with regard to promoter structure and methylation status in primary human mammary epithelial cells (HMECs). The coding sequence of TMS1 covers approximately 1.5 kb on chromosome 16p11.2 and is composed of three exons. The promoter region of TMS1 lacks a defined TATA box, but contains a 600 bp CpG island predicted on the basis of C+G content (69%), and CpG frequency (CpG observed/expected ¼ 0.82) (Figure 1a) . Evidence from the ESTs present in the Genbank database suggests the possibility of multiple, potentially tissue-specific transcription start sites. Therefore, it was necessary to precisely map the transcription start site used by breast cells. Primer extension analysis was performed using polyA+ selected RNA from MCF7 cells as a template. A single predominant transcription start site was mapped to approximately 79 bp upstream of the translation start site (Position +1177, Figure 1 ). This relative position was confirmed by 5 0 RACE, the longest product of which mapped to 13 bp downstream of this site (data not shown).
We next characterized the methylation status of 107 CpGs across 1.6 kb of the TMS1 locus in primary HMECs using bisulfite genomic sequencing. Briefly, DNA was modified with sodium bisulfite followed by amplification with primer sets A-D (Figure 1a ). The PCR products were then subcloned, and individual clones were sequenced. This approach allows for the assessment of the methylation status of every CpG site on independent chromosomal copies (alleles) derived from the original cell population. Four overlapping regions covering the TMS1 locus were analysed. Figure 1b shows the per cent of alleles methylated at each CpG site as determined from the analysis of eight to 10 individual alleles for each primer set. The TMS1 locus was characterized by an unmethylated domain that extended from 200 bp upstream to B1 kb downstream of the transcription start site, and encompassed the entire predicted CpG island plus B500 bp of additional downstream sequence (Figure 1b) . Of the few CpG sites that were methylated in this region, none were methylated on more than one allele. The 5 0 and 3 0 boundaries between the unmethylated CpG island and surrounding methylated DNA were similar in position to that of normal diploid fibroblasts (Stimson and Vertino, 2002) , and is thus likely representative of the pattern found in normal adult tissues.
In previous studies, we have shown that primary mammary epithelial cells (HMEC) and immortalized breast epithelial cells express TMS1, whereas four of nine breast cancer cell lines lack TMS1 expression and are methylated at the TMS1 CpG island (Conway et al., 2000) . These studies used methylation-specific PCR which allows for the analysis of only three to six individual CpG sites, and does not give any information regarding heterogeneity between individual alleles. To further investigate the role of methylation in TMS1 silencing, we determined the methylation status of 53 CpGs spanning the transcription start site (Primer set 'B', Figure 1a ) in primary, limited life-span mammary epithelial cells (HMEC), two immortalized but nontumorigenic breast epithelial cell lines (Hs578Bst, MCF10A), and seven breast cancer cell lines that either express TMS1 (MCF7, MDA MB468, and T47D), or do not express TMS1 (Hs578t, ZR75-1, MDA MB231, and SKBR3). As discussed above, HMECs were almost completely unmethylated at every CpG site across the region analysed (Figure 2) . Of the few methylated CpG sites that were observed, no single CpG site was methylated in more than one allele and no allele was methylated at more than one site (Figure 2 ). The immortalized breast epithelial cell lines Hs578Bst ( Figure 2 ) and MCF10A (not shown) were also nearly completely unmethylated; however, relative to HMECs, there was slight tendency for increased methylation at the 5 0 end of the region B, between À240 and À120 ( Figure 2 ). Breast cancer cell lines expressing TMS1 varied in their methylation pattern. MCF7 and MDA MB468 cells were predominantly unmethylated on all alleles (Figure 2 ). There did not appear to be any hot spots among the few sites that were methylated, but CpG sites in the 5 0 end of region B (À240 to À120) tended to be more frequently methylated in both cell lines. A third TMS1-expressing cell line, T47D, displayed a mixed methylation pattern composed of alleles that were predominantly methylated and those that were predominantly unmethylated (Figure 2 ). In contrast, three breast cancer cell lines lacking TMS1 expression (MB231, HS578T, and ZR75-1) exhibited nearly complete methylation at every CpG on all alleles (Figure 3) . A fourth nonexpressing cell line (SKBR3) also exhibited a predominantly methylated pattern on the majority of alleles, although a few unmethylated alleles were Bisulfitemodified DNA from cultured human mammary epithelial cells was treated with sodium bisulfite and amplified by PCR using primer sets A-D. The resulting PCR products were subcloned, and at least eight individual clones were sequenced for each amplification reaction. Per cent methylation was determined from the number of alleles containing a methylated CpG at each position relative to the total number of alleles analysed. The X-axis indicates nucleotide position relative to the transcription start site (zero) detected. Of 47 alleles analysed, 43 were predominantly methylated and four were predominantly unmethylated (representative alleles are shown in Figure 2 ).
In general, the overall patterns of DNA methylation correlated well with the levels of TMS1 expression as determined by semiquantitative reverse transcriptase PCR (RT-PCR) analysis for TMS1 message or Western blot analysis for TMS1 protein (Figure 4 ). Cell lines exhibiting predominantly unmethylated alleles (MCF7, MB 468) expressed levels of TMS1 that were equivalent to that of HMECs, whereas cell lines that were completely methylated at the TMS1 CpG island (MB231, Hs578T, and ZR75-1) did not express detectable TMS1 mRNA (after 35 cycles of RT-PCR, not shown) or protein ( Figure 4b ). As shown in Figure 2 , T47D cells contained a mixed population of methylated (6/9) and unmethylated (3/9) alleles. This observation is consistent with the interpretation that the methylation pattern observed in the T47D cells is a reflection of a mixed cell population in which some cells are unmethylated and express TMS1, while others are methylated and silenced. Alternatively, this pattern could be derived from allelic differences between chromosomes within each cell. In either case, gene expression should be proportional to the fraction of unmethylated chromosomes in the cell population. Indeed, the expression of TMS1 in T47D cells was approximately one-fifth that of HMEC cells (Figure 4 ). These data indicate that dense methylation of TMS1 correlates with gene silencing and those cell populations exhibiting at least some unmethylated alleles cells express TMS1.
One exception was the SKBR3 cell line. Although there were a few unmethylated alleles in the population (three of 47 analysed, see Treatment of completely methylated and silenced breast cancer cell lines (ZR75-1, Hs578t, and MDA MB231) with the demethylating agent 5-aza-CdR results in partial demethylation and re-expression of TMS1 (Conway et al., 2000) . To determine whether demethylation of particular CpG residues are important in TMS1 re-expression, bisulfite genomic sequencing was performed on DNA from ZR75-1, Hs578t, and MDA MB231 cells treated for 3 days with 0.5 mm 5-aza-dCR. These conditions are sufficient to achieve re-expression of TMS1 as determined by RT-PCR (Figure 4c ). In contrast to untreated cells, 5-aza-CdR-treated ZR75-1, Hs578t, and MDA MB231 revealed a partially methylated pattern, the degree of which varied between cell lines and between individual alleles within each cell line (Figure 3) . Interestingly, the overall methylation pattern revealed a distinct preference towards demethylation of the 5 0 end of the CpG island, in the region surrounding and upstream of the transcription start site (Figure 3 ). In fact, in the ZR75-1 cells, demethylation was observed only on two of 10 alleles analysed and was confined to the region between À197 and +59 ( Figure 3 ). Considering that there are relatively few demethylated alleles, the fact that gene expression was restored to B5% that of HMECs (Figure 4c ) suggests that these focally demethylated alleles express at near normal levels. These data suggest that demethylation of the region surrounding the transcription start is sufficient for re-expression of TMS1, and that transcription of TMS1 can occur despite dense methylation of downstream sequences.
We have previously shown that approximately 40% of primary breast tumors exhibited aberrant methylation of the TMS1 CpG island whereas paired adjacent normal tissues and normal breast tissues derived from patients without cancer were unmethylated (Conway et al., 2000) . To further detail the methylation patterns associated with breast cancer, four primary breast tumors and matched normal adjacent tissues were analysed by bisulfite genomic sequencing in region B ( Products were separated on a 6% polyacrylamide/Tris-borate-EDTA gel, dried, and exposed to X-ray film. Band intensities were quantified from digital images using Scion Image software. The ratio of TMS1: b-actin was determined and normalized to that of HMEC to allow for comparison between the cell lines. (b) Western blot analysis for TMS1 protein. Cell lysates (100 mg total protein) from the indicated cell lines were resolved by SDS-PAGE, blotted to PVDF membrane, and incubated with a rabbit anti-human TMS1 antiserum. Immunocomplexes were visualized using a HRP-conjugated secondary antibody and chemiluminescent detection. The blot was stripped and reprobed with an antibody to b-tubulin. (c) Re-expression of TMS1 following treatment with 5-aza-2 0 -deoxycytidine. Hs578t, MB231, and ZR75-1 cells were treated with 0.5 mm 5-aza-CdR for 72 h (+) or left untreated (À). RNA was reverse transcribed and amplified by PCR using primers specific for TMS1 (28 cycles) or b-actin (20 cycles). The ratio of TMS1: b-actin was determined as described in (a) and normalized to that of HMEC to allow for comparison between the cell lines. The data in panels a and c represent data from the same experiment methylation on all alleles analysed. In contrast, primary tumor samples showed a mixed methylation pattern. Again, there did not appear to be any hot spots of methylation, rather individual alleles were either predominantly methylated or predominantly unmethylated ( Figure 5 ). These data suggest that individual cells/ alleles are affected by aberrant methylation in an all-ornone manner in primary tumors, and that methylationassociated silencing of TMS1 affects subset of cells in the tumor.
We noted in the above analysis that cell lines that retain TMS1 expression exhibited increased methylation in the 5 0 end of region B relative to HMECs. To examine this further, we characterized the methylation status of 107 CpGs spanning regions B, C, and D (see Figure 1) in the breast cancer cell lines and compared that to the pattern seen in HMECs. Relative to HMECs, methylation tended to encroach into the 5 0 end of the CpG island in the MCF7 and MB468 cells, but the center of the CpG island remained relatively devoid of methy- Figure 1 . The amplification product was subcloned and sequenced. Each row represents an independent subclone. For presentation purposes, not every allele analysed is shown. For tumor #2, a total of two of 26 alleles analysed were methylated; for tumor #3, a total of three of 16 alleles analysed were methylated. Open circles, unmethylated CpG sites; closed circles, methylated CpGs. The nucleotide position of CpG sites relative to the upstream HindIII site (upper) and transcription start site (lower) are as indicated at the top lation ( Figure 6 ). Methylation of the remainder of the CpG island was observed only in the context of fully methylated alleles. For example, T47D cells could be separated into methylated and unmethylated alleles. Of eight alleles sequenced in regions B and C, five were predominantly methylated and three alleles were relatively devoid of methylation. At the 3 0 end, however (region D), all alleles were completely methylated. This relation is graphically represented in Figure 6 by separating unmethylated from methylated alleles. Interestingly, the pattern observed for the unmethylated component of the T47D cell population was similar to that of the other TMS1 positive cell lines in that there was an increase in methylation at the 5 0 end of region B relative to HMECs, but beyond that, there was relatively little methylation in the center of the CpG island except in the completely methylated allele component ( Figure 6 ). In contrast to the dynamics in methylation observed at the 5 0 methylation boundary, there was little difference in the location of the 3 0 methylation boundary between any of the cells tested (with the exception of fully methylated cell lines). As expected, the silent cell line MDA MB231 was completely methylated across the entire CpG island (Figure 6 ). These data suggest that the mechanism that normally acts to maintain the 5 0 methylation boundary in normal breast epithelial cells may be compromised in breast cancer cells.
Both our methylation analysis and the 5-aza-dC reactivation studies suggested that the sequences im- Figure 1 . The amplification product was subcloned and sequenced. Per cent methylation was determined from the number of alleles containing a methylated CpG at each position relative to the total number of alleles analysed. The X-axis indicates nucleotide position relative to the transcription start site. Note that for T47D cells data are presented for all alleles (T47D), the predominantly unmethylated alleles (n ¼ 3, T47D unmethylated) or the predominantly methylated alleles (n ¼ 5, T47D methylated) (see text) mediately upstream of transcription start were most critical with regard to methylation-mediated silencing. To test this hypothesis, we used transient transfection assays to determine the effect of DNA methylation on the TMS1 promoter. A luciferase reporter construct was constructed by cloning a 1254 bp genomic fragment extending from an upstream HindIII site to an NcoI site at the translation start site of TMS1 (À1179 to +79, see Figure 1 ) into an NcoI site in the pGL3 vector such that it replaced the translation start site of the luciferase reporter gene. The resulting construct was transfected into breast cancer cell lines and luciferase activity measured as an indication of TMS1 promoter activity. Both TMS1-positive (MB468, MCF7, and T47D) and TMS1-negative (MB231, SKBR3, and HS578t) cell lines were capable of driving expression from the TMS1 promoter, and there was no apparent relation between the ability to transactivate the TMS1 promoter and methylation-dependent silencing of endogenous TMS1 (Figure 7a) . In vitro methylation of pTMS1-1254Luc with M.SssI methyltransferase (which methylates all CpG residues) resulted in an almost complete abrogation of luciferase activity when transfected into either TMS1-positive or TMS1-negative cell lines (Figure 7b ). These data indicate that all of the breast cancer cell lines tested are capable of transactivating an unmethylated TMS1 promoter, and can repress a methylated TMS1 promoter, regardless of the status of the endogenous promoter-luciferase construct into breast cancer cell lines. A 1254 bp HindIII-NcoI fragment of the TMS1 promoter was cloned upstream of the luciferase reporter to form pTMS1-1254L. The indicated cell line was transfected with 2.5 mg pTMS1-1254L or pGL3 and 0.5 mg pRL-TK using the lipofectAMINE reagent. Luciferase activity is shown relative to that of the empty pGL3 vector after correction for transfection efficiency. (b) Methylation-dependent repression of TMS1. The pTMS1-1254L reporter (2.5 mg) was methylated (M) or mock-methylated (U) with M.SssI and transfected into the indicated cell line. pRL-TK (0.5 mg) was added as a control for transfection efficiency. Cells were harvested at 48 h and luciferase activity determined. Data are presented as the mean 7 standard deviation of triplicate determinations after correction for transfection efficiency. *, not significantly above background. (c) Effect of regional methylation on TMS1 promoter activity. Schematic representation of the pTMS1-1254L TMS1 reporter construct used in methylation cassette assays (not to scale). Vertical lines, CpG sites; H, HindIII; B, Bsu36I; A, ApaI, N, NcoI.; vec, vector; luc, luciferase coding region. Fragments of the TMS1 promoter derived from the pTMS1-1254L luciferase construct were methylated in vitro with M.SssI methyltransferase, ligated to the remainder of the pTMS1-1254L plasmid, and the ligation mix was transfected directly into MDA MB231 cells. Parallel reactions were performed in which the same fragment was left unmethylated (by omitting the methyltransferase) to reconstitute a fully unmethylated construct. pRL-TK (0.5 mg) was added to control for transfection efficiency. Data for each patch methylated construct are represented as the luciferase activity relative to the corresponding mock-methylated control. Data represent the mean 7 standard deviation for the indicated number (n) of independent determinations after correction for transfection efficiency. (d) Patch 'demethylation' experiments were performed as described in panel c except that the indicated promoter fragment was mock-methylated, and ligated to the remainder of the pTMS1-1254L vector which had been methylated with M.SssI. Parallel reactions were performed in which the corresponding fragment was methylated to reconstitute a fully methylated construct. Data for each construct are represented as the luciferase activity relative to the corresponding fully methylated control. Data represent the mean 7 standard deviation for the indicated number (n) of independent determinations after correction for transfection efficiency TMS1 gene. Together with the finding that TMS1-negative breast cell lines can be reactivated after treatment with 5-aza-CdR, these data suggest that absence of TMS1 expression in TMS negative breast cancer cells is related to DNA methylation and not a lack of necessary transactivating factors. The above studies do not specifically address the role of methylation on promoter activity as the entire construct was methylated, including CpG sites in the vector and luciferase coding region, which could have effects on luciferase expression. We therefore used a 'patch' methylation strategy to delineate the relative effects of methylation on different regions of the TMS1 promoter. Various cassettes from the TMS1 promoter were methylated in vitro with M.SssI methyltransferase, ligated to the remainder of the pTMS1-1254Luc plasmid and the ligation mix was transfected directly into MDA MB231 cells. Parallel reactions were performed in which the same fragment was left unmethylated (by omitting the methyltransferase) to reconstitute a fully unmethylated promoter (Figure 7c ). Relative to the fully unmethylated state, methylation of the 200 bp (16 CpGs) immediately surrounding transcription start site (À122 to +79) resulted in a 70% repression of transcriptional activity. This effect did not appear to be related to the number or density of methylated CpG sites, as methylation of the adjacent 200 bp fragment (À337 to À122), which is equal in density of CpGs (16 CpGs/200 bp), had relatively little effect on transcriptional activity (Figure 7c) . Indeed, methylation of 1000 bp upstream of À122, a pattern which mimics that observed in MB468 or MCF7 cells, showed only a 25% reduction in promoter activity, while the addition of sequences downstream of À121 resulted in 95% repression. We further investigated the relative importance of the 200 bp proximal promoter fragment, by determining the effect of 'demethylation' of this fragment within the context of a fully methylated expression construct. These studies were similar to the above analyses, except that in this case the entire vector (including the luciferase gene) was methylated, and ligated to promoter fragments that were either methylated or mock-methylated. Remarkably, demethylation of the region from À122 to +79 resulted in a threefold derepression of luciferase activity, even within the context of a fully methylated 5 kb construct, whereas demethylation of the adjacent 200 bp fragment (À337 to À122) had no effect (Figure 7d ). Together, these data indicate that the sequences immediately surrounding transcription start (À122 to +79) are critical to the expression of TMS1.
Discussion
In this study, we address the role of methylation in the silencing of TMS1, a recently described proapoptotic gene that is aberrantly methylated and silenced in human breast cancers. Using bisulfite genomic sequencing to detail the methylation status of individual CpGs across the TMS1 locus, we find that TMS1 silencing is not correlated with methylation of specific CpG sites, but rather is associated with the dense methylation of the TMS1 CpG island. Breast tumor cell lines containing exclusively methylated TMS1 copies do not express TMS1, while in partially methylated cell lines such as T47D, the levels of TMS1 expression are directly related to the percentage of methylated TMS1 alleles present in the cell population. Breast cancer cell lines in which TMS1 was methylated and silenced re-expressed TMS1 after treatment with 5-aza-CdR, and were capable of driving transcription from an unmethylated TMS1 promoter, indicating that methylation is the only impediment to TMS1 expression. Using a methylation cassette assay, we show that selective methylation of as few as 16 CpGs limited to the region surrounding transcription start site significantly represses TMS1 promoter activity.
We defined the transcription start site and characterized the methylation status of the TMS1 locus in primary human mammary epithelial cells. With very few exceptions, CpGs in the region from À300 to + 900 bp relative to the transcription start site were unmethylated whereas flanking DNA was heavily methylated. Interestingly, the unmethylated domain mapped in the HMEC cells extends well beyond what would be predicted to be a CpG island based on C+G content and CpG density (see Figure 1) , suggesting that there are other factors (e.g. chromatin architecture) that dictate the zone of protection from methylation in normal cells. Recently, we showed that in human fibroblasts, the TMS1 CpG island is flanked by DNAseI hypersensitive sites that form at the 5 0 and 3 0 methylation boundaries suggesting that there are physical boundaries occurring at the level of chromatin that define the boundaries of methylation in normal cells (map positions À130 and +950, see Figure 1) ) (Stimson and Vertino, 2002) . We have proposed that the integrity of these chromatin boundaries is important in maintaining the unmethylated status of the TMS1 CpG island in normal cells. Consistent with this hypothesis, whereas methylation tended to accumulate in the 5 0 end of the CpG island in breast cancer cells relative to HMEC cells, it rarely involved sequences downstream of the 5 0 hypersensitive site (À130) except in the context of fully methylated alleles. Likewise, methylation at the 3 0 end of the CpG island rarely extended upstream of +950, the position of the 3 0 hypersensitive site. We have previously shown that silencing of TMS1 in human fibroblasts is accompanied by hypoacetylation of histones H3 and H4, and loss of CpG island-specific DNAseI hypersensitive sites, indicating that the methylation-dependent repression of TMS1 involves histone modification and local changes in chromatin architecture (Stimson and Vertino, 2002) . In this study, we show that methylation also has direct effects on the TMS1 promoter. Selective methylation of only 16 CpG sites encompassing the region from À130 to +70 repressed transcription by 70%. Methylation of the adjacent 16 CpGs (À337 to À122) had little effect on promoter activity. In fact, methylation of the region from À1177 to À122 -a scenario that recapitulates the endogenous methylation pattern observed in the MCF7 or MDA MB468 cells -had relatively little effect on TMS1 transcription. These data argue that the repressive effect of methylation is not a simple function of generalized methylation density nor a position-independent signal transmissible in cis as has been suggested in other cases (Kass et al., 1993; Hsieh, 1994; Curradi et al., 2002) , but that the location of methylation has a direct impact on transcription from the TMS1 promoter. These findings were similar to that observed at the p16 locus in colon cancer cells where methylation of the CpG sites immediately surrounding transcription start had a greater effect on reporter activity than other regions of the CpG island promoter (Gonzalgo et al., 1998) . The critical nature of demethylation in this region is further suggested by the finding that the region upstream of +70 remains preferentially demethylated after treatment of methylated and silent cell lines with 5-aza-CdR. Although the cis elements that regulate TMS1 expression have yet to be defined, the region downstream of À122 constitutes the minimal promoter in breast cells as determined by deletion analysis (J Levine and P Vertino, unpublished results). This region includes consensus sites for transcription factors whose binding to DNA is sensitive to methylation (E2F and AP-2), as well as those (Sp1) that are insensitive to methylation (Eden and Cedar, 1994; Campanero et al., 2000) . Thus, while chromatin remodeling and dense methylation are likely to be important in the maintenance of gene repression once it has been established, the encroachment of methylation into the 5 0 region may have a local effect on the TMS1 promoter that contributes to the initial silencing event.
Methylation tended to affect independent TMS1 alleles in an all-or-none manner, and in breast cancer cell lines the degree of gene repression was correlated with the per cent of the population exhibiting completely methylated alleles (e.g. T47D cells). Cell lines for which most alleles remained protected within the central portion (À120 to +950) of the CpG island expressed similar levels of TMS1. This is in contrast to several other CpG islands that have been analysed in detail in primary tumors which have implicated the methylation of specific regions or 'hot-spots' in transcriptional repression (Cameron et al., 1999; Danam et al., 1999; Kinoshita et al., 2000; Song et al., 2002) . The correlation between complete methylation of the CpG island and gene expression levels and the near absence of intermediate methylation patterns within the central part of the CpG island suggests that dense methylation and gene silencing are tightly coupled. In fact, remodeling of CpG island chromatin and gene silencing may be a prerequisite for the dense methylation associated with silent TMS1 alleles. It has been proposed that active transcription is one factor that prevents the de novo methylation of CpG islands. Transcriptional activators can compete with the assembly of a methylated template into a repressive chromatin structure (Kass et al., 1997; Curradi et al., 2002) and the binding of transcription factors to their recognition sequence blocks de novo methylation by DNMTs (Han et al., 2001) . However, the finding that many CpG islands remain unmethylated in nonexpressing cells (reviewed in Bird, 2002) argues that the absence of transcription per se is not enough to trigger aberrant methylation and another event (e.g. loss of a cis-acting protective function) may be involved. At the TMS1 locus, de novo methylation does not appear to be due to a generalized lack of transcriptional capacity as all of the TMS1-negative breast cell lines were capable of driving transcription from an unmethylated TMS1 promoter. A recent study by Song et al. (2002) showed that de novo methylation of a GSTP1 CpG island transgene reintroduced in prostate cancer cells occurred only when random 'seeds' of methylation were first introduced and promoter activity was compromised. The authors proposed that transient or heterogeneous loss of GSTP1 expression in precancerous prostate tissues leaves the GSTP1 CpG island susceptible to de novo methylation. Our data extend such a model to include the possibility that spreading or seeding of methylation into the proximal promoter could facilitate this process by attenuating transcriptional activity.
Primary breast tumors exhibited a mixed methylation pattern with subsets of completely methylated and completely unmethylated alleles, whereas adjacent normal tissues exhibited only completely unmethylated alleles. Although there may be some degree of normal tissue contamination that contributes to the pool of unmethylated TMS1 alleles, this all-or-none methylation pattern suggests that silencing of TMS1 only occurs in a subpopulation of cells in the tumor. At present, the consequences of TMS1 silencing on breast epithelial cells are unknown. TMS1 encodes a 21 kDa protein containing an N-terminal pyrin/PAAD domain and a C-terminal caspase recruitment domain, two domains found in proteins that mediate apoptosis and inflammation. Ectopic expression of TMS1 promotes apoptosis and suppresses the growth of breast cancer cells (Conway et al., 2000) . Decreased levels of TMS1 result in reduced sensitivity to etoposide (Masumoto et al., 1999) , suggesting that loss of TMS1 might confer resistance to stress-induced apoptosis. Recent evidence suggests that TMS1 interacts with procaspase-1 and regulates the processing of proinflammatory cytokines (Srinivasula et al., 2002; Wang et al., 2002) . Loss of TMS1 through methylation-mediated silencing also might be one mechanism in which breast tumor cells evade a local immune response.
There is currently a great deal of interest in the use of methyltransferase inhibitors to reactivate silenced tumor suppressor genes in cancer. Interestingly, treatment of fully methylated and silenced breast cancer cells with 5-aza-CdR resulted in the preferential demethylation of sequences surrounding the transcription initiation site. This pattern was somewhat surprising considering the mechanism of action of 5-aza-CdR. 5-aza-CdR acts only after its incorporation into DNA where it is acted on by DNMTs, resulting in the irreversible binding of the enzyme to the analog base and cellular depletion of soluble DNMT1 within 12 h of treatment (Ferguson et al., 1997) . Consequently, 5-aza-CdR inhibits the methylation of newly synthesized DNA strands, and would be expected to result in a loss of methylation on a strand-by-strand basis with each round of replication. Since azacytosine residues persist in DNA for only 24-48 h, new synthesis of DNMTs could potentially remethylate previously unmethylated DNA. Like TMS1, 5-aza-CdR-induced demethylation of the p16 locus in bladder cancer cell lines was similarly localized to the region surrounding transcription start (Gonzalgo et al., 1998; Bender et al., 1999) . It was proposed that this pattern resulted from the protection of the region from remethylation by transcriptional activators bound to the transiently unmethylated promoter. In support of this hypothesis, the same region of TMS1 that is protected after 5-aza-CdR treatment corresponds to the minimal promoter as determined by deletion analyses (J Levine and P Vertino, unpublished results), as well as to the region critically affected by methylation in the methylation cassette assays. These data suggest that one needs only to achieve and to maintain the demethylation of a small number of CpGs to re-establish transcriptional competency at TMS1, and perhaps other aberrantly methylated genes.
In summary, our data suggest a model in which dense methylation and gene silencing are tightly coupled events involving local remodeling of CpG island chromatin. The transition to this stably repressed state may be facilitated by the progressive spreading and/or seeding of methylation into the 5 0 end of the CpG island, which could act to attenuate transcriptional activity or to interfere with the integrity or function of the 5 0 methylation/chromatin boundary. This process affects individual chromosomal copies of TMS1 in an all-ornone manner such that at any one time only a subset of cells in a tumor may have lost TMS1 expression and gained a survival advantage. Further study on the dynamics of TMS1 methylation and repression and on the function of TMS1 in breast cell apoptosis should provide a better understanding of how TMS1 silencing impacts on breast tumor progression.
Materials and methods

Breast cell lines and primary tumors
HMECs were obtained from Clonetics (Walkersville, MD, USA). Cell lines were maintained in DMEM (4.5 g/l glucose) plus 10% FCS and 2 mm glutamine. For Hs578Bst, Hs578t, and T47D cells, medium was supplemented with 10 mg/ml insulin. SKBR3 was maintained in McCoy's 5A medium plus 10% FCS and 2 mm glutamine. For 5-aza-2 0 deoxycytidine treatment, 10 6 cells were seeded into T75 flasks, and treated the next day with 0.5 mm 5-aza-2 0 -deoxycytidine for 72 h. Genomic DNA isolated from primary breast tissues and tumors was generously provided by Dr. Sara Sukumar (Johns Hopkins University, Baltimore, MD, USA). Primary breast tissues were obtained immediately following surgical resection at Johns Hopkins University Hospital or Duke University and frozen at À80 o C. Tumors were estimated to contain at least 50% tumor cells by microscopic examination of representative sections.
Primer extension
Total cellular RNA was isolated from MCF7 cells by solubilization in guanidine isothiocyanate and acid-phenol extraction (Chomczynski and Sacchi, 1987) . Poly(A)+ mRNA was selected on oligo-dT cellulose columns as previously described (Conway et al., 2000) . Primer TMSgen1309AS (5 0 -GTC AGG TTC TCC AGC GCA TCC-3 0 ) was endlabeled with T4 polynucleotide kinase and g-32 P-ATP and hybridized to 2 mg poly (A)+ RNA followed by a 30 min extension with AMV reverse transcriptase at 421C (Promega). Reaction products were denatured and separated by electrophoresis on a 8% polyacrylamide/8M Urea/1 Â TBE sequencing gel, dried onto Whatman paper, and exposed to X-ray film using an intensifying screen (Kodak, BioMAX-MS). The size of the extension product was determined by comparison to end-labeled single-stranded FX174/Hinf I DNA markers.
Bisulfite sequencing
Genomic DNA was treated with sodium bisulfite as described (Herman et al., 1996) . Bisulfite-modified DNA (B50 ng) was amplified by PCR for bisulfite sequencing under the following reaction conditions: 67 mm Tris-HCl (pH 8.8), 16.6 mm NH 4 SO 4, 6.7 mm EDTA, 10 mm b-mercaptoethanol, 6.7 mm MgCl 2 , 2 mm dNTP, and 1 mm each primer in a 50 ml reaction. conditions. A hot start was performed (5 min, 951C) followed by 35 cycles of PCR (951C, 30 s; 551C, 30 s; 721C, 30 s) with a final extension of 721C for 10 min. Primers were designed to avoid potential methylation sites (CpGs) so that both methylated and unmethylated DNA would be amplified equally. The resulting amplification pools were subcloned into the pCRII-TOPO vector using the TOPO TA Cloning kit (Invitrogen). Eight to twelve individual subclones were isolated per PCR reaction and sequenced by the Emory University Sequencing facility. Primer pairs used for bisulfite genomic sequencing were: A: 
Reverse transcriptase-PCR
Total RNA was isolated from log-phase cells by solubilization in guanidine isothiocyanate and acid-phenol extraction (Chomczynski and Sacchi, 1987) . Total RNA (6 mg) was pretreated with amplification grade DNAse I (Life Technologies) and reverse transcribed using random hexamer primers and MMLV-reverse transcriptase (Life Technologies). 1/30th of the reverse transcriptase reaction (200 ng of starting RNA) was used in a PCR reaction. The PCR conditions were: 67 mm Tris-HCl (pH 8.8), 16.6 mm NH 4 SO 4, 6.7 mm EDTA, 10 mm bmercaptoethanol, 4.7 mm MgCl 2 , 10% DMSO, 2 mm dNTP, and 400 nm each primer in a 25 ml reaction. Reactions were spiked with 0.2 mCi [a-P 32 ]dCTP. A hot start was performed (5 min, 951C), followed by 18-35 cycles of 951C, 30 s; 551C, 30 s; 721C, 30 s. Reaction products were separated by electrophoresis on a 6% polyacrylamide/Tris-borate-EDTA gel, dried onto Whatman paper and exposed to X-ray film (Biomax-MS, Kodak). Band intensities were quantified from the scanned images using Scion Image software (Scion Corporation). Preliminary experiments were performed using cycle numbers ranging from 20 to 35 for each transcript. We determined that 20 cycles (b-actin) and 28 cycles (TMS1) were within the linear range of amplification for each message. Primers used were: TMS1, 5 0 -TGG GCC TGC AGG AGA TG-3 0 and 5 0 -ATT TGG TGG GAT TGC CAG-3 0 ; b-actin, 5 0 -CCT TCC TGG GCA TGG AGT CCT G-3 0 , and 5 0 -GGA GCA ATG ATC TTG ATC TTC-3 0 .
Luciferase reporter assays
A genomic HindIII-NcoI fragment containing 1254 bp upstream of TMS1 translation start codon was cloned into pGL3 luciferase reporter plasmid (Stratagene) to form the construct pTMS1-1254L. Cells (2.5-5 Â 10 5 ) were plated into six-well dishes and transfected the next day with 2.5 mg pTMS1-1254L or pGL3 control plasmid using 6 ml of LipfectAMINE (Life Technologies) per well. Transfections included 0.5 mg of a Renilla luciferase reporter (pRL-TK) as a control for transfection efficiency. Firefly luciferase and renilla luciferase activities were determined after 48 h using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's directions. For experiments analysing the effects of methylation on promoter activity, pTMS1-1254L was methylated in vitro with SssI methylase in the presence of 0.016 mm S-adenosylmethionine at 371C for 4 h (New England Biolabs). The completeness of the methylation reaction was verified by PvuI restriction digest. For cassette methylation experiments, various fragments of the TMS1 promoter were generated by digestion of pTMS1-1254L with NcoI plus HindIII, BamHI, or ApaI (10 um/mg), and methylated or mock-methylated with M.SssI as described above. Fragments were purified from agarose gels and ligated to the remainder of the methylated or mock-methylated pTMS1-1254L plasmid using the Quick Ligation kit (New England Biolabs). The ligation reactions were then ethanol precipitated and transfected directly into MDA MB231 cells using the LipofectAMINE reagent (Invitrogen). pRL-TK (0.5 mg) was included as a transfection control. The firefly luciferase and renilla luciferase activities were measured after 48 h using the Dual-Luciferase Reporter Assay System (Promega). Results were normalized to the activity of renilla luciferase to correct for transfection efficiency.
